





06-4-03

06-04-2003

6.4.03

RECEIVED OPR
PH 1:14
2003 JUN 11
ASSIGNMENTS DIV

Form PTO-1594 (Rev. 10/02) OMB No. 0651-0027 (exp. 6/30/2005) Tab settings $\Rightarrow \Rightarrow \Rightarrow$ ∇		REC T.  102464141	U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office			
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.						
1. Name of conveying party(ies): Boehringer Ingelheim Pharmaceuticals, Inc. <input type="checkbox"/> Individual(s) <input type="checkbox"/> Association <input type="checkbox"/> General Partnership <input type="checkbox"/> Limited Partnership <input checked="" type="checkbox"/> Corporation-State <input type="checkbox"/> Other _____ Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		2. Name and address of receiving party(ies) Name: OPR Development, L.P. Internal Address: _____ Address: _____ Street Address: 1501 Wakarusa Drive City: Lawrence State: KS Zip: 66047 <input type="checkbox"/> Individual(s) citizenship _____ <input type="checkbox"/> Association _____ <input type="checkbox"/> General Partnership _____ <input checked="" type="checkbox"/> Limited Partnership Delaware <input type="checkbox"/> Corporation-State _____ <input type="checkbox"/> Other _____ If assignee is not domiciled in the United States, a domestic representative designation is attached: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No (Designations must be a separate document from assignment) Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No				
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other _____ Execution Date: 04/22/2003						
4. Application number(s) or registration number(s): A. Trademark Application No.(s) _____ _____ Additional number(s) attached <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		B. Trademark Registration No.(s) 2,173,441 _____				
5. Name and address of party to whom correspondence concerning document should be mailed: Name: Timothy X. Witkowski Internal Address: Boehringer Ingelheim Corp. _____ _____ Street Address: 900 Ridgebury Road _____ City: Ridgefield State: CT Zip: 06877		6. Total number of applications and registrations involved: 1 7. Total fee (37 CFR 3.41).....\$ 40.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account 8. Deposit account number: 02-2955				
DO NOT USE THIS SPACE						
9. Signature. <table border="0" style="width: 100%;"> <tr> <td style="width: 40%;"> Timothy X. Witkowski Name of Person Signing </td> <td style="width: 30%; text-align: center;">  Signature </td> <td style="width: 30%; text-align: right;"> June 3, 2003 Date </td> </tr> </table> <div style="text-align: right; margin-top: 10px;"> <input checked="" type="checkbox"/> 2 </div>				Timothy X. Witkowski Name of Person Signing	 Signature	June 3, 2003 Date
Timothy X. Witkowski Name of Person Signing	 Signature	June 3, 2003 Date				

Mail documents to be recorded with required cover sheet information to:
 Commissioner of Patent & Trademarks, Box Assignments
 Washington, D.C. 20231

06/04/2003 TDIAZ1 00000156 022955 2173441
 01 FC:8521 40.00 CH

TRADEMARK
 REEL: 002745 FRAME: 0705

TRADEMARK ASSIGNMENT

RECEIVED OPR
2003 JUN -4 PM 1:
ASSIGNMENTS


WHEREAS Boehringer Ingelheim Pharmaceuticals, Inc., a Delaware corporation located and doing business at 900 Ridgebury Road, Ridgefield, Connecticut 06877, has adopted, used, and is using the CAFCIT[®] trademark which was registered in the United States Patent and Trademark Office on July 14, 1998, and accorded Registration No. 2,173,441; and


WHEREAS OPR Development, L.P., a Delaware limited partnership located and doing business at 1501 Wakarusa Drive, Lawrence, Kansas 66047, wishes to acquire the CAFCIT[®] trademark.

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration, the receipt of which is hereby acknowledged, Boehringer Ingelheim Pharmaceuticals, Inc. hereby assigns to OPR Development, L.P. all right, title, and interest in the CAFCIT[®] trademark and Registration No. 2,173,441, together with all goodwill associated with the CAFCIT[®] trademark and Registration No. 2,173,441, effective April 22, 2003 ("the Effective Date"). Boehringer Ingelheim Pharmaceuticals, Inc. further authorizes the United States Patent and Trademark Office to record the CAFCIT[®] trademark and Registration No. 2,173,441 as the property of OPR Development, L.P. together with the right to sue and collect damages for past infringement thereof.

IN WITNESS WHEREOF, Boehringer Ingelheim Pharmaceuticals, Inc. and OPR Development, L.P. have executed this Assignment as of the Effective Date.

Boehringer Ingelheim Pharmaceuticals, Inc. OPR Development, L.P.

Signature: 
Name: STEVE MARLIN
Title: V.P. BUS. DEV.

Signature: 
Name: [unclear]
Title: general partner